Home › Research › Topics › blood-based
blood-based
706 studies tagged blood-based, dated 1989-01-01 to 2026-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival 2026-11-01
- Longitudinal plasma biomarkers and multimodal PET across APOE ε4 genotypes: a prospective cohort study 2026-11-01
- Concurrent cognitive, behavioral and systemic physiological features mark preclinical Alzheimer's disease 2026-10-30
Studies
706 studies carry this tag.
Date range
1989 to 2026
Top journals
- Alzheimer's & dementia : the journal of the Alzheimer's Association 126
- Journal of Alzheimer's disease : JAD 54
- Alzheimer's & dementia (Amsterdam, Netherlands) 46
- Alzheimer's research & therapy 36
- medRxiv 29
196 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
Tau proteins and amyloid-β (Aβ) peptides are the current recognized cerebrospinal fluid (CSF) biomarkers used as an aid in the diagnosis of Alzheimer's disease (AD).
-
36/100
We performed unbiased analysis of steroid-related compounds to identify novel Alzheimer's disease (AD) plasma biomarkers using liquid chromatography-atmospheric pressure chemical ionization-mass spectroscopy.
-
It is possible to create a blood-based screening algorithm that works across both serum and plasma that provides a comparable screening accuracy to that obtained from CSF analyses.
-
It is not well known whether Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers are associated with brain damage in cognitively normal elderly.
-
An ideal diagnostic test for Alzheimer's disease (AD) should be non-invasive and easily applicable.
-
Despite a variety of testing approaches, it is often difficult to make an accurate diagnosis of Alzheimer's disease (AD), especially at an early stage of the disease.
-
High CSF p-tau and low ratios of Aβ(1-42)/Aβ(1-40) and Aβ(1-42)/Aβ(1-38), respectively, were specific for AD.
-
The CSF Abeta42/Abeta40 ratio improves differentiation of AD patients from VaD, DLB and non-AD dementia patients, when compared to Abeta42 alone, and is a more easily interpretable alternative to the combination of Abeta42, p-tau and t-tau when differentiating AD from either FTD or non-AD dementia.
-
CSF Aβ levels are altered in a subset of patients with early PD and relate to memory impairment.
-
Low or decreasing plasma Aβ42 during the follow-up is associated with cognitive decline.
-
52/100
In regression analyses across the whole study sample adjusted for age, sex, and diagnostic group, there was no relationship between HbA1c or fasting glucose and CSF tau, p-tau 182, or Abeta42 levels.
-
In this study, we determined the diagnostic accuracy of cerebrospinal fluid (CSF) biomarkers to predict development of Alzheimer's disease (AD) within five years in patients with mild cognitive impairment (MCI).
-
Cerebrospinal fluid (CSF) has become a matrix for biomarker discovery and development in recent years.
-
Alzheimer's disease (AD) pathology is estimated to develop many years before detectable cognitive decline.
-
36/100
There is an urgent need for Alzheimer's disease (AD) biomarkers-especially in the context of clinical trials.
-
Alzheimer's disease (AD) is a progressive mental disorder disease, which affects 26.6 million people worldwide and estimated increments can be 100 millions by 2050.
-
45/100
After correction for multiple comparisons, a strong positive association between CSF Abeta42 levels and glucose metabolism was identified for 2 extensive clusters located in the right temporal, prefrontal and anterior cingulate cortices.
-
47/100
Reduction in CSF Abeta(42), likely reflecting Abeta aggregation in the brain, is associated with brain atrophy in the preclinical phase of AD.
-
55/100
Efforts to use plasma levels of Abeta peptides as AD biomarkers or disease-staging scales have failed.
-
A blood-based biomarker of Alzheimer's disease (AD) progression could be instrumental in targeting asymptomatic individuals for treatment early in the disease process.
-
While cerebrospinal fluid (CSF) biomarkers are of use in the prediction and diagnosis of Alzheimer's disease our understanding of the background effects of age and the ApoE genotype is limited.
-
An 8-plex version of an isobaric reagent for the quantitation of proteins using shotgun methods is presented.
-
Blood-based tests for the differential diagnosis of Alzheimer's disease (AD) are under intensive investigation and have shown promising results with regard to Abeta40 and Abeta42 peptide species in incipient AD.
-
In the diagnostic workup of relatively young dementia patients, CSF NFL levels may play a role in the discrimination between FTLD and EAD, especially in combination with Abeta42 and p-tau181 analysis.
-
A panel of possible CSF biomarkers for AD has been identified using proteomic methods.
-
Evidence supports an important role for beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD).
-
Statins may modulate the phosphorylation of tau in humans and this effect may depend on the CNS availability of the statin.
-
Our results support further efforts to prospectively validate the use of Q Abeta42/p-tau as a biomarker to discriminate between AD and VaD.
-
To improve clinical, neuropsychological and behavioural characterisation of the cerebrospinal fluid (CSF) biomarkers beta-amyloid((1-42)) protein (Abeta42), protein tau (tau) and tau phosphorylated at threonine 181 (P-tau181) across diagnostic dementia categories, a prospective study was set up.
-
Cerebrospinal fluid (CSF) biological markers may be of valuable help in the diagnosis of dementia.
-
Lowered 3alpha,5alpha-THP levels appear promising as a biomarker in dementia, but further work is needed to establish the sensitivity and specificity of these findings in AD.
-
We assessed cerebrospinal fluid (CSF) levels of tau and other biomarkers of neurodegenerative disease.
-
In this study we aimed to evaluate the possibility of using cerebrospinal fluid (CSF) tau, Abeta(1-42) and inflammatory cytokines for diagnosis of Alzheimer's disease (AD) and vascular dementia (VD).
-
The recently developed ultrasensitive bio-barcode assay was used to measure the concentration of amyloid-beta-derived diffusible ligands (ADDLs), a potential soluble pathogenic Alzheimer's disease (AD) marker, in the cerebrospinal fluid (CSF) of 30 individuals.
-
A nanoscale optical biosensor based on localized surface plasmon resonance (LSPR) spectroscopy has been developed to monitor the interaction between the antigen, amyloid-beta derived diffusible ligands (ADDLs), and specific anti-ADDL antibodies.
-
By comparing the cerebrospinal fluid (CSF) proteome between Alzheimer's disease (AD) patients and controls, it may be possible to identify proteins that play a role in the disease process and thus to study the pathogenesis of AD.
-
The quantification of mRNA in postmortem human brain is often made complicated by confounding factors.
-
These results demonstrate increased production of the proinflammatory cytokine, TNFalpha and decreased production of the anti-inflammatory cytokine TGFbeta in patients with MCI at risk to develop AD, suggesting a propensity towards inflammation in this patient group and indicating that CNS inflammation is a early hallmark in the pathogenesis of AD.
-
Plasma Abeta measures increase with age, but, in contrast to reports on familial AD, plasma Abeta measures were neither sensitive nor specific for the clinical diagnosis of mild cognitive impairment or sporadic AD.
-
The main objective was to investigate the acetylcholinesterase E (AChE) activity in the cerebrospinal fluid (CSF) of patients with three common dementia disorders.
-
The diagnosis of Alzheimer's disease (AD) is currently based on clinical and neuropsychological examination.
-
Amyloid beta protein 40 (Abeta40) and 42 Abeta42, major components of senile plaque amyloids, are physiological peptides present in the brain, cerebrospinal fluid (CSF) and plasma.
-
The two most frequently examined biomarkers in the diagnosis of dementia are cerebrospinal fluid (CSF) tau and beta-amyloid(1-42) (Abeta(1-42)).
-
The reliability of cerebrospinal fluid (CSF)-tau and CSF-beta-amyloid assays for diagnosis of Alzheimer's disease and other dementing disorders such as frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and Creutzfeldt-Jakob disease (CJD) is reviewed.
-
The objective of this study was to compare cerebrospinal fluid (CSF) levels of the light subtype of the neurofilament proteins (NFL), tau, and beta-amyloid42 (Abeta42) in individuals with moderate or severe white matter changes (WMC) and in those with mild or no WMC.
-
Potential cerebrospinal fluid (CSF) markers for Alzheimer's disease (AD) include tau protein, the 42 amino-acid form of amyloid beta (amyloid beta(1-42)) and apolipoprotein E (apoE).
-
X-34, a lipophilic, highly fluorescent derivative of Congo red, was examined as a histochemical stain for pathological changes in Alzheimer's disease (AD).
-
In view of current (AChE inhibitors) and future (e.g. anti-Aβ aggregators), development and evaluation of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) has become a rapidly growing research field.
-
59/100
In this study, levels of total A(beta)x-40 and A(beta)x-42 were elevated early in dementia and levels of both peptides were strongly correlated with cognitive decline.
-
Earlier studies have shown elevated levels of tau protein and decreased levels of amyloid beta42 in cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD).
From across this tag
6 of the 704 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 6. The same 6 appear here every time.
- Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease
- Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease
- Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years
- Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease
- Plasma P-tau181 to Aβ42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease
- Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment